Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | Q9HBH1 | 1/20 | 0.35 | |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 11/20 | 0.34 |
| ▸ | MMP2 | P08253 | 11/20 | 0.34 |
| ▸ | MMP1 | P03956 | 10/20 | 0.34 |
| ▸ | MMP7 | P09237 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 6/20 | 0.33 |
| ▸ | MMP8 | P22894 | 4/20 | 0.33 |
| ▸ | MMP13 | P45452 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 2/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.32 |
| ▸ | MMP20 | O60882 | 1/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | MMP10 | P09238 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676064 | 1.00 | HIF1A (0.37) | HIF1APDFCA2CA1MMP3 | |
| Hydrochloric Acid SCHEMBL20491962 | 0.80 | HIF1A (0.32) | HIF1ACA2CA1 | |
| Hydrochloric Acid SCHEMBL20491965 | 0.80 | HIF1A (0.32) | HIF1ACA2CA1 | |
| SCHEMBL20721129 | 0.80 | MMP3 (0.49) | MMP3MMP2MMP1MMP7MMP9 | |
| SCHEMBL8690110 | 0.80 | MMP3 (0.35) | PDFMMP3MMP2MMP1MMP7 | |
| SCHEMBL20721130 | 0.80 | MMP3 (0.49) | MMP3MMP2MMP1MMP7MMP9 | |
| SCHEMBL1706304 | 0.79 | HIF1A (0.34) | HIF1APDFCA2CA1MMP3 | |
| SCHEMBL4300898 | 0.78 | MMP3 (0.37) | MMP3MMP2MMP1MMP7MMP9 | |
| Hydrochloric Acid SCHEMBL2286815 | 0.78 | HIF1A (0.33) | HIF1APDFCA2CA1MMP3 | |
| SCHEMBL21543027 | 0.77 | CNR2 (0.36) | PDFCA2MMP9CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-3909949-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11078208-B1 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3577110-B1 | 8-OXETAN-3-YL-3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL SUBSTITUTED COMPOUNDS AS HIV INHIBITORS | GILEAD SCIENCES INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10752636-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10294234-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180258097-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-09-13 | — | — | US | disclosed |
| EP-1697348-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885PDF 3663/4885CA2 2712/4885 |
| US-20180258097-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885PDF 3663/4885CA2 2712/4885 |
| US-11078208-B1 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885PDF 3663/4885CA2 2712/4885 |
| US-10752636-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885PDF 3663/4885CA2 2712/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | HIF1A 3923/4885PDF 1754/4885CA2 3870/4885 |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | HASPIN, NFATC1, NHERF1 | HIF1A 419/4885PDF 4173/4885CA2 2320/4885 |
| US-10294234-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | HIF1A 1070/4885PDF 3663/4885CA2 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.